Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

AIDS

Volumn 15, Issue 7, 2001, Pages 847-855

  Van Der Valk, M ^a,b   Gisolf, E H ^a,b   Reiss, P ^a,b   Wit, F W N M ^a,b   Japour, A ^a,b   Weverling, G J ^a,b   Danner, S A ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Combined therapy; HIV; Lipodystrophy; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

CHOLESTEROL; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPODYSTROPHY; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; STAVUDINE; TIME FACTORS;

EID: 0035805176     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200105040-00005     Document Type: Article

References (22)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. 'Buffalo hump' in men with HIV-1 infection
3. Visceral abdominal-fat accumulation associated with the use of indinavir
4. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
5. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
6. Lipodystrophic syndromes in a cohort of HIV-1 infected patients receiving HAART with a protease inhibitor
7. Lipodystrophy in patients naive to HIV protease inhibitors
8. Lipodystrophy associated with nevirapine-containing antiretroviral therapies
9. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
10. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
11. Nucleoside reverse transcriptase inhibitor-associated mitochondrial toxicity as an etiology for lipodystrophy
12. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
13. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
14. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity
15. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides
16. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
17. Increased stavudine concentrations in plasma and cerebrospinal fluid: A possible interaction with ritonavir and/or indinavir?
18. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS)
19. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations
20. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
21. Fat redistribution and metabolic changes in patients with HIV infection
22. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study